Bone Biologics Corporation
Σύμβολο: BBLG
NASDAQ
1.8001
USDΤιμή αγοράς σήμερα
-0.1011
Λόγος P/E
0.0004
Δείκτης PEG
1.58M
MRK Cap
- 0.00%
DIV Απόδοση
Bone Biologics Corporation (BBLG) Οικονομικές καταστάσεις
Ισολογισμός
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 3 | 7.5 | 6.7 | ||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.net-receivables | 0 | 0.3 | 0.6 | 0 | ||||||||||||||||
balance-sheet.row.inventory | 0 | -0.3 | -0.6 | 0 | ||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 0.7 | 1 | 0 | ||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 3.7 | 8.5 | 6.7 | ||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-assets | 0 | 3.7 | 8.5 | 6.7 | ||||||||||||||||
balance-sheet.row.account-payables | 0 | 0.4 | 0 | 0.1 | ||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 0 | -0.8 | 0 | ||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | ||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 0.5 | 2.5 | 0 | ||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-liab | 0 | 0.8 | 2.5 | 0.1 | ||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -80.9 | -72 | -70.5 | ||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 83.8 | 77.9 | 77 | ||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 2.9 | 5.9 | 6.6 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 3.7 | 8.5 | 6.7 | ||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-equity | 0 | 2.9 | 5.9 | 6.6 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||
Total Investments | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-debt | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.net-debt | 0 | -3 | -7.5 | -6.7 |
Κατάσταση ταμειακών ροών
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -8.9 | -1.5 | -1.6 | ||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0.2 | 0.3 | 0.2 | ||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 0.1 | -0.2 | -0.3 | ||||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.account-payables | 0 | 0.3 | 0.8 | -0.4 | ||||||||||||||||
cash-flows.row.other-working-capital | 0 | -0.1 | -1 | 0 | ||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -0.9 | -2.2 | 0.5 | ||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 5 | 4.4 | 6.9 | ||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0 | 1.1 | ||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 5 | 4.4 | 7.9 | ||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -4.5 | 0.9 | 6.7 | ||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 3 | 7.5 | 6.7 | ||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 7.5 | 6.7 | 0 | ||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | -9.6 | -3.6 | -1.2 | ||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.free-cash-flow | 0 | -9.6 | -3.6 | -1.2 |
Σειρά κατάστασης λογαριασμού αποτελεσμάτων
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.gross-profit | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 9.4 | 3.7 | 1.1 | ||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 9.4 | 3.7 | 1.1 | ||||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -2.2 | 0.8 | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 0.5 | 2.2 | -0.5 | ||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 0.5 | 2.2 | -0.5 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -2.2 | 0.8 | ||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 9.4 | -0.7 | 0 | ||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.operating-income | 0 | -9.4 | -3.7 | -1.1 | ||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -8.9 | -1.5 | -1.6 | ||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 0 | -2.2 | 0 | ||||||||||||||||
income-statement-row.row.net-income | 0 | -8.9 | 0.7 | -1.6 |
Συχνές ερωτήσεις
Ποιο είναι το Bone Biologics Corporation (BBLG) το σύνολο του ενεργητικού?
Bone Biologics Corporation (BBLG) το συνολικό ενεργητικό είναι 3737763.000.
Ποια είναι τα ετήσια έσοδα της επιχείρησης?
Τα ετήσια έσοδα είναι N/A.
Ποιο είναι το περιθώριο κέρδους της επιχείρησης?
Το περιθώριο κέρδους της επιχείρησης είναι 0.000.
Ποια είναι η ελεύθερη ταμειακή ροή της επιχείρησης?
Η ελεύθερη ταμειακή ροή είναι -17.887.
Ποιο είναι το καθαρό περιθώριο κέρδους της επιχείρησης?
Το καθαρό περιθώριο κέρδους είναι 0.000.
Ποια είναι τα συνολικά έσοδα της επιχείρησης?
Τα συνολικά έσοδα είναι 0.000.
Ποια είναι η Bone Biologics Corporation (BBLG) καθαρό κέρδος (καθαρό εισόδημα)?
Το καθαρό κέρδος (καθαρό εισόδημα) είναι -8948731.000.
Ποιο είναι το συνολικό χρέος της επιχείρησης?
Το συνολικό χρέος είναι 0.000.
Ποιος είναι ο αριθμός των λειτουργικών εξόδων?
Τα λειτουργικά έξοδα είναι 9428303.000.
Ποιος είναι ο αριθμός των ταμειακών διαθεσίμων της εταιρείας?
Τα ταμειακά διαθέσιμα της επιχείρησης είναι 0.000.